PDS Biotech's PDS01ADC Shows Promising Phase 2 Results in Advanced Prostate Cancer
PDSB sits 39% above its 52-week low of $0.703.
Summary
PDS Biotechnology announced positive preliminary Phase 2 results for its investigational IL-12 immunocytokine, PDS01ADC, in patients with metastatic castration-resistant prostate cancer, demonstrating a median progression-free survival of 9.6 months.
Key Events · Product Development and Regulatory · PDSB
-
Positive Phase 2 Data
An NCI-led study of PDS01ADC in 3rd line metastatic castration-resistant prostate cancer (mCRPC) showed a median progression-free survival (PFS) of 9.6 months.
-
Significant PSA Decline Observed
The study also reported a median PSA decline of 40%, with 6 of 16 patients achieving greater than 50% decline, indicating a promising clinical response.
-
Results Presented at AACR Conference
Preliminary results were presented at the American Association of Cancer Research special conference on prostate cancer research, highlighting the potential of PDS01ADC.
Analysis · PDSB · Life Sciences
This filing reports encouraging preliminary Phase 2 clinical data for PDS01ADC, a key asset in PDS Biotech's immuno-oncology pipeline, in a challenging patient population with limited treatment options. The observed median progression-free survival of 9.6 months and significant PSA declines suggest clinical benefit and validate the potential of the company's tumor-targeting IL-12 immunocytokine. For a micro-cap biotech, positive clinical validation of its pipeline is a critical de-risking event and could significantly impact investor sentiment and future development prospects. This follows recent positive news regarding patent allowance and a Phase 3 amendment for its lead asset, PDS0101, further strengthening the company's overall pipeline narrative.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.6% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.2M. The 52-week trading range was $0.70 to $2.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.